Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Bortezomib Maintenance in High-Risk AML
NCT01465386Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2011
- Primary completion
- Jan 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in acute myeloid leukemia (AML), sponsored by Fred Hutchinson Cancer Center. Started Nov 2011; status: terminated.
02
Drugs
bortezomib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01465386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01465386.